Aktieanalys

Physitrack: Prioritising positive cash flow holds back topline growth - Redeye

Redeye Publicerad: 01 Mar 07:27

Redeye has updated our estimates and fair value range in response to Physitrack’s Q4 2023 report, which slightly missed our topline expectations due to lower-than-anticipated sales in the Wellness division. Despite this, we anticipate a profitable 2024, with a softer first half followed by a stronger second half. The adjustments to our fair value range account for the impact of a weaker EUR/SEK and our forecast adjustments, resulting in a new Base case of SEK35 (previously SEK38) per share. Considering that the share is trading at EV/EBIT 13x and EV/Sales 1.2x based on 2024e, we continue to observe a significant discount compared to its peers.

Länk till analysen i sin helhet: https://www.redeye.se/research/986749/physitrack-prioritising-positive-cash-flow-holds-back-topline-growth?utm_source=finwire&utm_medium=RSS

Nyheter om Physitrack

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!